Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells by Wing, Peter A.C. et al.
ReportHypoxic and pharmacological activation of HIF
inhibits SARS-CoV-2 infection of lung epithelial cellsGraphical abstractHighlightsd Hypoxia downregulates SARS-CoV-2 receptors ACE2 and
TMPRSS2 and inhibits viral entry
d Hypoxic signaling inhibits SARS-CoV-2 replication and
particle genesis via HIF-1a
d HIF prolyl hydroxylase inhibitors are a potential therapeutic
option for COVID-19Wing et al., 2021, Cell Reports 35, 109020
April 20, 2021 ª 2021 The Authors.
https://doi.org/10.1016/j.celrep.2021.109020Authors
Peter A.C. Wing, Thomas P. Keeley,
Xiaodong Zhuang, ..., Emma J. Hodson,
Tammie Bishop, Jane A. McKeating
In brief
Wing et al. demonstrate that key aspects
of the SARS-CoV-2 life cycle are
dependent on cellular oxygen tension.
Activation of the cellular oxygen-sensing
pathway inhibits SARS-CoV-2 infection,
highlighting a key cellular pathway that
could be exploited as a potential
therapeutic avenue for COVID-19.ll
OPEN ACCESS
llReport
Hypoxic and pharmacological activation
of HIF inhibits SARS-CoV-2
infection of lung epithelial cells
Peter A.C. Wing,1,2,15 Thomas P. Keeley,1,3,15 Xiaodong Zhuang,1 Jeffrey Y. Lee,4 Maria Prange-Barczynska,1,3
Senko Tsukuda,1 Sophie B. Morgan,5 Adam C. Harding,6 Isobel L.A. Argles,1 Samvid Kurlekar,1 Marko Noerenberg,4,7
Craig P. Thompson,8 Kuan-Ying A. Huang,9,10 Peter Balfe,1 Koichi Watashi,11,12 Alfredo Castello,4,7 Timothy S.C. Hinks,5
William James,6 Peter J. Ratcliffe,1,3,13 Ilan Davis,4 Emma J. Hodson,13,14,16 Tammie Bishop,1,3,16
and Jane A. McKeating1,2,16,17,*
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Sciences (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
3Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK
4Department of Biochemistry, University of Oxford, Oxford, UK
5RespiratoryMedicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department
of Medicine, Experimental Medicine, University of Oxford, Oxford, UK
6Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK
7MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
8Peter Medawar Building for Pathogen Research, Department of Zoology, University of Oxford, Oxford, UK
9Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan
10Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
11Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
12Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan
13Francis Crick Institute, London, UK
14Department of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK




https://doi.org/10.1016/j.celrep.2021.109020SUMMARYCOVID-19, caused by the novel coronavirus SARS-CoV-2, is a global health issue with more than 2 million
fatalities to date. Viral replication is shaped by the cellular microenvironment, and one important factor to
consider is oxygen tension, in which hypoxia inducible factor (HIF) regulates transcriptional responses to
hypoxia. SARS-CoV-2 primarily infects cells of the respiratory tract, entering via its spike glycoprotein bind-
ing to angiotensin-converting enzyme 2 (ACE2). We demonstrate that hypoxia and the HIF prolyl hydroxylase
inhibitor Roxadustat reduce ACE2 expression and inhibit SARS-CoV-2 entry and replication in lung epithelial
cells via an HIF-1a-dependent pathway. Hypoxia and Roxadustat inhibit SARS-CoV-2 RNA replication,
showing that post-entry steps in the viral life cycle are oxygen sensitive. This study highlights the importance
of HIF signaling in regulating multiple aspects of SARS-CoV-2 infection and raises the potential use of HIF
prolyl hydroxylase inhibitors in the prevention or treatment of COVID-19.The COVID-19 pandemic, caused by the novel coronavirus
SARS-CoV-2, is a global health issue. Although multiple public
health approaches, including mass vaccination and social
distancing, are needed to bring the pandemic under control,
there is an urgent need for prophylactic measures or early treat-
ment that can be targeted to vulnerable groups. This is of partic-
ular importance given the emergence of SARS-CoV-2 variants
and the uncertainty of future vaccine efficacy. SARS-CoV-2 pri-
marily targets the respiratory tract and infection is mediated by
spike (S) protein binding to the human angiotensin-converting
enzyme 2 (ACE2), where the transmembrane protease serine 2This is an open access article und(TMPRSS2) triggers fusion of the viral and cell membranes (Hoff-
mann et al., 2020; Wan et al., 2020). ACE2 is highly expressed in
epithelial cells of the respiratory tract as well as those of the kid-
ney and intestine (Hamming et al., 2004; Tipnis et al., 2000; Zhao
et al., 2020b). Although COVID-19 is mild in most cases, a
defining feature of severe disease is systemic low-oxygen levels
(hypoxemia), which is often disproportionate to lung injury. There
is evidence to suggest that this profound hypoxemia may alter
the ability of SARS-CoV-2 to infect host cells. Hypoxia has
been reported to regulate the replication of a number of viruses
(Jiang et al., 2006; Kraus et al., 2017; Zhao et al., 2020a; ZhuangCell Reports 35, 109020, April 20, 2021 ª 2021 The Authors. 1





Figure 1. Hypoxia or FG-4592 (Roxadustat) inhibits the expression of SARS-CoV-2 entry factors in vitro and in vivo
(A) ACE2 and TMPRSS2 transcript levels across a panel of cell lines: HepG2 hepatoma, SH-SY5Y neuronal, RKO colon epithelial, Caco-2 colon epithelial, U937
monocyte/macrophage, Vero E6 monkey epithelial kidney, Calu-3 airway epithelial, A549 airway epithelial, EA.hy926 umbilical vein endothelial, and U-2OS
osteosarcoma endothelial. Cells with minimal ACE2 and TMPRSS2 mRNA expression (SH-SY5Y, RKO, U937, A549, EA.hy926, and U-2OS) are displayed as
black dots. Data are expressed relative to HPRT (hypoxanthine-guanine phosphoribosyl transferase).
(B) ACE2-expressing cell lines from (A) were treated with FG-4592 (50 mM) or 1%O2 for 24 h, and ACE2 and TMPRSS2mRNAwas assessed. Data are presented
relative to untreated cells; n.d., not detected.
(C) HepG2 cells were treated with increasing concentrations of FG-4592 for 24 h, and ACE2/TMPRSS2mRNA was quantified and expressed as a percentage of
the maximal induction/inhibition. CAIX mRNA levels were analyzed in parallel as an established HIF-1a-regulated host gene.
(D) HepG2 cells were cultured at 1% O2 for 16 h and were re-oxygenated over a 0.5–24-h period, and ACE2/TMPRSS2 mRNA levels were analyzed at the
indicated times.
(E) Calu-3 cells were treated with an increasing concentration of FG-4592 (0–100 mM) or 18%, 5%, 3%, and 1% O2 for 24 h, and ACE2/TMPRSS2 protein
expression was assessed by immunoblot. Densitometric values are expressed relative to b-actin.
(F) siRNAs targeting either HIF-1 or 2a were delivered into Calu-3 cells individually or in combination. Cells were treated with FG-4592 (50 mM) or 1% O2 for 24 h,
and ACE2 mRNA levels were quantified. Data are expressed relative to the normoxic siScramble (siScram) control. Statistical significance was determined by
(legend continued on next page)






OPEN ACCESSet al., 2020), enhancing the replication of Epstein-Barr virus
(Jiang et al., 2006; Kraus et al., 2017), but suppressing HIV and
influenza infection (Zhao et al., 2020a; Zhuang et al., 2020),
demonstrating that the interaction between hypoxia signaling
and viral infection is context specific and dependent on both
the host cell and viral species. Furthermore, hypoxia has been
reported to either induce or, in some cases, suppress ACE2
expression in lung pulmonary arterial smooth muscle cells
(PASMCs) (Zhang et al., 2009, 2019), hematopoietic stem cell
precursors (Joshi et al., 2019), and hepatocarcinoma cells
(Clarke et al., 2014). Because the effects of low oxygen on
both ACE2 expression and SARS-CoV-2 replication are likely
to be cell context dependent, we evaluated whether hypoxia al-
ters SARS-CoV-2 entry and replication in lung epithelial cells.
Mammalian cells adapt to low oxygen through an orchestrated
transcriptional response regulated by hypoxia-inducible factor
(HIF), a heterodimeric transcription factor comprising HIF-1a or
HIF-2a subunits, which is regulated by oxygen-dependent and
-independent stress signals. When oxygen is abundant, newly
synthesized HIFa subunits are rapidly hydroxylated by HIF
prolyl-hydroxylase domain (PHD) enzymes and are targeted for
polyubiquitination and proteasomal degradation. In contrast,
when oxygen is limited, HIFa subunits translocate to the nucleus,
dimerize with HIF-1b, and activate the transcription of genes
involved in cell metabolism, proliferation, pulmonary vasomotor
control, and immune regulation (Kaelin and Ratcliffe, 2008; Pal-
azon et al., 2014; Urrutia and Aragones, 2018). Defining how hyp-
oxia or activation of HIF affects the SARS-CoV-2 life cycle in lung
epithelial cells will increase our understanding of disease patho-
genesis and inform therapeutic strategies. Specifically, this has
the potential for pharmacological intervention because drugs
that inhibit the PHD enzymes to stabilize HIF (Pugh and Ratcliffe,
2017; Sanghani and Haase, 2019) are either in advanced clinical
trials for the treatment of renal anemia or are licensed for clinical
use (Roxadustat in China [Chen et al., 2019a, 2019b) and Japan
[Akizawa et al., 2020a, 2020c, 2020d] and Daprodustat in Japan
[Akizawa et al., 2020b]).
The host proteins ACE2 and TMPRSS2 are key determinants
of SARS-CoV-2 cell entry (Hoffmann et al., 2020). We screened
several commonly used cell lines for ACE2 and TMPRSS2
mRNA, and only four demonstrated notable expression of
ACE2: HepG2 (hepatoma), Caco-2 (colonic adenocarcinoma),
Calu-3 (lung adenocarcinoma), and Vero E6 (monkey kidney
epithelia) (Figure 1A). We noted that Vero E6 do not express
TMPRSS2 mRNA. To assess the role of HIF in regulating these
entry factors, we cultured the cells under hypoxic conditions
(1% O2) or after being treated with an inhibitor targeting the
PHDenzymes (FG-4592/Roxadustat), which stabilizes HIFa sub-
units and upregulates HIF target gene transcription. Both treat-
ments reducedACE2 and TMPRSS2 transcripts, with themagni-
tude of effect varying between cell lines (Figure 1B). Successfultwo-way ANOVA. *denotes significance relative to normoxic siRNA (siScram) at
dition.
(G) C57BL/6micewere treatedwith FG-4592 (oral, 10mg/kg twice daily) or 10%O
the lungs was determined by qPCR.
mRNA expression for each target gene (relative to ActB) was compared between
Data are presented as means ± SD from (A–D), n = 3–6; (E) n = 3; (F) n = 4; and (Gactivation of the HIF-signaling pathway was confirmed by induc-
tion of the HIF target genes carbonic anhydrase IX (CAIX), N-Myc
downstream regulated 1 (NDRG1), and Egl-9 homolog or HIF
prolyl hydroxylase 3 (EGLN3 or PHD3) (Figure S1A). In HepG2
cells, in which transcript suppression was most evident, FG-
4592 downregulated ACE2 and TMPRSS2 mRNA levels in a
dose-dependent manner concomitant with its induction of
CAIX, NDRG1, and EGLN3 transcription (Figures 1C and S1B).
Reoxygenation of cells previously exposed to hypoxia led to a re-
covery of both ACE2 and TMPRSS2 mRNA to near pre-hypoxic
levels (Figure 1D), suggesting a specific action of the HIF-PHD
pathway. To assess whether hypoxia/FG-4592 regulation is
evident at the protein level, we also measured ACE2 and
TMPRSS2 protein expression in human lung epithelial Calu-3
cells, a more physiologically relevant cell type for studying
SARS-CoV-2 infection. Culturing Calu-3 cells under hypoxic
conditions or treating with FG-4592 significantly reduced ACE2
protein expression in a dose-dependent manner with maximum
suppression >50 mMFG-4592 or <3% oxygen (Figure 1E) and no
effect on cell viability (Figure S1C). Similar, but more modest, ef-
fects were observed with TMPRSS2 expression (Figure 1E). The
hypoxia-induced changes in ACE2 (and, to a lesser extent,
TMPRSS2) protein expression were observed in HepG2 cells
(Figure S1D). Any differences between mRNA and protein levels
may, in part, reflect the cleavage and secretion of the TMPRSS2
catalytic domain or that additional hypoxia-stimulated factors
regulate protein stability and/or expression. To assess the role
of HIF, we silenced HIF-1a or HIF-2a expression in hypoxic
or FG-4592-treated Calu-3 cells with small interfering RNAs
(siRNAs). siRNA-mediated silencing of HIF-1a (either alone or
in combination with HIF-2a) restored ACE2 mRNA levels in FG-
4592-treated or hypoxic Calu-3 cells (Figure 1F). In contrast,
silencing HIF-2a did not restore ACE2mRNA levels in either con-
dition tested and resulted in a modest decrease under normoxic
conditions (Figure 1F). siRNA knockdown was verified by quan-
tifying the relevant HIFa transcripts CAIX, NDRG1, EGLN3, and
VEGFA (Figure S2). These data reveal a role for HIF-1a in repres-
sing ACE2 mRNA and protein expression.
To expand these observations to an in vivo setting, mice
were treated with hypoxia (10% O2) or FG-4592 for 24 h, with
a dosing regimen (oral, 10 mg/kg twice daily) similar to that pre-
viously used to induce polycythemia (Schley et al., 2019) and
the clinical dose for treating renal anemia (Provenzano et al.,
2016). Both treatments reduced Ace2 and Tmprss2 transcripts
in the lung, along with an increase in Endothelin 1 (Edn1) mRNA
(Figure 1G), a host gene previously reported to be induced by
HIF activation in the respiratory tract (Hickey et al., 2010).
Collectively, these data show a role for hypoxia in reducing
ACE2 and TMPRSS2 in vitro across multiple cell lines, and
this is recapitulated in the lungs of mice after systemic hypoxia
or FG-4592 treatment.18% O2, whereas indicates significance relative to the control siRNA per con-
2 for 24 h, andmRNA expression ofAce2, Tmprss2, andHIF target geneEdn1 in
biological groups using a Student’s two-tailed t test, **p < 0.01, ****p < 0.0001.
) n = 4 (n = 3 for Ace2 in FG-4592 or vehicle-treated mice). See also Figure S1.







Figure 2. Hypoxia or FG-4592 (Roxadustat) inhibits SARS-CoV-2 entry in a HIF-1a-dependent manner
(A) Calu-3 and primary bronchial epithelial cells (PBECs) pre-treated for 24 h with either FG-4592 (50 mM) or 1% O2 were infected with SARS-CoV-2 pseudo-
particle (pp), and infection wasmeasured after 48 h. To demonstrate the specificity of entry via the spike protein, the ppwas incubated with anti-spikemonoclonal
antibody (mAb) FI-3A (1 mg/mL) for 30 min before infection. Data are expressed relative to untreated (UT) cells.
(B) Calu-3 cells were treated with FG-4592 (50 mM) or 1% O2 and infected with wild-type (WT) or mutant (D614G or Furin knockout [KO]) SARS-CoV-2pp, and
infection was measured 48 h later. Data are expressed relative to UT cells.
(C) Calu-3 cells were cultured at 1%O2 for 16 h and re-oxygenated over a 0.5–6-h period. Cells were infected with SARS-CoV-2pp at the indicated times, and the
pp entry levels were measured 48 h after infection. Data are expressed relative to normoxic cells.
(D) siRNAs against HIF-1a and HIF-2a were delivered into Calu-3 cells either individually or in combination. Cells were treated with FG-4592 (50 mM) 24 h after
transfection and then infected with SARS-CoV-2pp. Data are expressed relative to an siScrambled (siScram) control. * denotes significance relative to control
siRNA (siScram) at 18% O2, whereas # indicates significance relative to control siRNA per condition.
(E) Calu-3 cells were treated with FG-4592 (50 mM) or cultured at 1% O2 for 24 h before inoculation with SARS-CoV-2 (MOI 0.001) for 2 h. Infected cells were
washed to remove the residual inoculum, and viral replication was assessed 24 h after infection by measuring intracellular and extracellular viral RNA along with
infectious titer (particle infectivity) through quantification of plaque-forming units (PFU)/mL. As a control to measure the cellular response to FG-4592 or 1% O2,
CAIX mRNA was quantified by qPCR. All data (except particle infectivity) is expressed relative to the UT control.
(legend continued on next page)






OPEN ACCESSWe hypothesized that the HIF-dependent reduction in ACE2
expression would limit SARS-CoV-2 entry into naive target cells.
To assess that, we used lentiviral pseudoparticles (pp) express-
ing SARS-CoV-2-encoded spike glycoprotein and confirmed
that infectivity was ACE2 dependent by infection of human em-
bryonic kidney cells engineered to express ACE2 (Figure S3A).
Culturing Calu-3 or primary bronchial epithelial cells (PBECs) un-
der hypoxic conditions or treating with FG-4592 significantly
reduced SARS-CoV-2pp infection (Figure 2A). In contrast, viral
pp expressing the vesicular stomatitis virus glycoprotein (VSV-
G) infected Calu-3 cells and PBEC with comparable efficiency
at both oxygen levels (Figure S3B), demonstrating a SARS-
CoV-2-specific phenotype. We next sought to test whether hyp-
oxia/FG-4592 limits entry of the novel SARS-CoV-2 spike protein
variants; these have emerged throughout the course of the
pandemic, with some conferring a fitness advantage to viral en-
try. The most notable of these to date, D614G, is globally preva-
lent in the pandemic, consistent with a reported fitness advan-
tage for infecting cells in the upper respiratory tract (Weissman
et al., 2021; Korber et al., 2020). Further, deletion of the unique
furin cleavage site (which mediates membrane fusion) in the
SARS-CoV-2 spike protein has been observed in vitro (Davidson
et al., 2020) and in animal models of infection (Peacock et al.,
2020). Importantly, hypoxia or FG-4592 treatment of Calu-3 cells
reduced infection of pp containing either the spike variant to a
similar degree as the wild type (Figure 2B). Reoxygenation of
hypoxic Calu-3 cells induced a recovery of SARS-CoV-2pp entry
(Figure 2C), consistent with our earlier data showing post-hypox-
ic recovery of ACE2 and TMPRSS2 mRNA levels. Silencing
HIF-1a reversed the anti-viral effect of FG-4592 (Figure 2D),
demonstrating that HIF-1a represses SARS-CoV-2 entry,
consistent with its role in regulating ACE2. In contrast, we
observed a negligible effect of silencing HIF-2a on SARS-CoV-
2 entry (Figure 2D). In summary, these data show that hypoxic/
FG-4592 activation of HIF-1a represses ACE2 and impairs entry
of SARS-CoV-2 entry pp.
We next assessed whether our observations with SARS-CoV-
2pp translate to authentic viral replication. Infecting hypoxic (1%
O2) Calu-3 cells with SARS-CoV-2 (Victoria 01/20 strain) resulted
in a 90% reduction in viral RNA compared with that of normoxic
cells (Figure 2E). A similar repression in SARS-CoV-2 RNA levels
was also observed when culturing Calu-3 cells in 3% oxygen
(Figure S4A). Importantly, FG-4592 (50 mM)mimicked the hypox-
ic inhibition of SARS-CoV-2 replication, leading to a significant
reduction in the genesis of new particles (Figure 2E). To define
whether hypoxia altered the infectivity of SARS-CoV-2 particles,(F) Calu-3 cells were treated with FG-4592 (50 mM) for 24 h before inoculation with
were washed to remove the residual inoculum, and viral replication was assessed
relative to the UT control.
(G) Calu-3 cells were treated with increasing concentrations of Daprodustat (GS
infected with SARS-CoV-2, and viral replication was assessed 24 h later. Data a
(H) siRNA targeting either HIF-1 or 2awas delivered into Calu-3 cells individually or
1% O2 before inoculating with SARS-CoV-2 (MOI 0.001). Intracellular RNA was q
siScramble (siScram) control. * denotes significance relative to the control siRNA
per condition.
Data are presented asmeans ±SD from (A) n = 4 (Calu-3) and n = 5 (PBEC donors)
E, and G) or two-way (D and F) ANOVA. *p or #p < 0.05, **p or ##p < 0.01, ***p owe assessed the ratio of RNA copies per plaque-forming unit
(PFU), finding no significant difference between virus produced
from cells at either 18% O2 or 1% O2 (9.3 3 10
3 ± 6.7 3 103
and 2.6 3 103 ± 1.6 3 103 means ± SD. RNA copies/PFU,
respectively). Notably, we demonstrated comparable antiviral
efficacy of FG-4592 treatment against the recently identified
B.1.1.7 (United Kingdom) and B1.351 (South Africa) SARS-
CoV-2 variants (Figure 2F). Treating Calu-3 cells with FG-4592
or two additional PHD inhibitors of the same class: Daprodustat
and Molidustat, inhibited SARS-CoV-2 replication in a dose-
dependent manner with maximal inhibition noted at approxi-
mately 6 mM (Figure 2G), which is in the range of reported plasma
levels in human subjects after oral administration of these drugs
at clinical doses (Provenzano et al., 2016). Efficacy of either PHI
treatment or hypoxic culture in the activation of HIF was vali-
dated by assessing the induction of CAIX mRNA (Figures 2E
and S4B). siRNA silencing of HIF-1a, but not HIF-2a, in Calu-3
cells reversed the hypoxic or FG-4592-mediated suppression
of viral infection, demonstrating a role for HIF-1a in repressing
SARS-CoV-2 RNA replication (Figure 2H). These data show a
key role for HIF-1a in repressing ACE2-dependent, authentic
SARS-CoV-2 entry and infection.
To define whether hypoxia signaling regulates additional post-
entry steps in the SARS-CoV-2 life cycle, we evaluated the effect
of hypoxia on viral replication when applied throughout or after
virus inoculation. Hypoxia reduced viral RNA levels in both con-
ditions and at all multiplicities of infection (MOIs) tested (Fig-
ure 3A). Importantly, treating SARS-CoV-2-infected Calu-3 with
FG-4592 or hypoxia for 24 h significantly reduced both intracel-
lular and extracellular SARS-CoV-2 RNA (Figure 3B). To further
define the post-entry effects of HIFs on viral replication, we in-
fected Calu-3 cells and treated them with either FG-4592 or
1% oxygen 8 h later, once replication complexes were estab-
lished. We noted a significant reduction in intracellular and extra-
cellular viral RNA with both treatments and an induction of CAIX
mRNA (Figure 3C), demonstrating a role for HIFs in the regulation
of post-entry viral RNA replication.
Given the marked reduction in the cellular viral RNA burden
observed under hypoxic conditions, we sought to understand
the effect of hypoxia on the initial establishment of viral replica-
tion complexes and quantities of positive genomic-strand viral
RNA at the single-cell level. Using single-molecule fluorescence
in situ hybridization (smFISH), wemeasured the effect of hypoxia
and FG-4592 on positive-strand viral RNAs within the first 6 h of
infection, which represents the first cycle of infection (eclipse
phase) before the secretion of infectious particles (Figure S5).SARS-CoV-2 Victoria 01/20, B1.1.7, or B1.351 (MOI 0.003) for 2 h. Infected cells
24 h after infection bymeasuring intracellular viral RNA, and data are expressed
K: 1278863), Molidustat (Bay 85-3934), and Roxadustat (FG-4592) and were
re expressed relative to UT cells.
in combination, and 24 h after transfectionwas treatedwith FG-4592 (50 mM) or
uantified 24 h after infection, and data are expressed relative to the normoxic
(siScram) at 18%O2, whereas # indicates significance relative to control siRNA
; and (B–G) n = 4. Statistical significancewas determined using a one-way (A, B,
r ###p < 0.001, ****p or ####p < 0.0001. See also Figures S2–S4.




Figure 3. Hypoxia or FG-4592 (Roxadustat) inhibits SARS-CoV-2
replication post-entry
(A) Calu-3 cells were treated with 1% O2 before or after infection with SARS-
CoV-2 at the indicated MOIs, and intracellular RNA was quantified by qPCR
24 h later. Data are expressed as RNA copies 3 108/mg of total cellular RNA.
(B) Calu-3 cells were inoculated with SARS-CoV-2 (MOI 0.001) for 2 h; un-
bound virus was removed by washing, and cells were treated with FG-4592
(50 mM) or cultured at 1% O2. Viral replication was assessed by measuring
6 Cell Reports 35, 109020, April 20, 2021
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OPEN ACCESSHypoxia and FG-4592 treatment significantly reduced the levels
of viral RNA per cell (Figures 4A and 4B). We noted a reduction in
the frequency of infected cells, as judged by the detection of
genomic RNA (Figure 4C). Because de novo generated viral par-
ticles were first detected at 6 h after infection (Figure S5), these
RNA signals represent primary infection events.
In conclusion, we describe striking inhibitory effects of hypoxia
and FG-4592 (Roxadustat) treatment on SARS-CoV-2 entry
(including spike variants), replication, and secretion of infectious
particles in lung epithelial cells. These effects were mediated by
a HIF-1a-dependent repression of SARS-CoV-2 replication, in
concert with the reduced expression of ACE2 across a range
of cell lines and mouse lung tissue. Of note, there are reports
of hypoxic induction ofACE2 gene expression in other cell types,
albeit often transient (Clarke et al., 2014; Joshi et al., 2019; Zhang
et al., 2009). Although this contrasts with our findings, the
discrepancy may reflect the minimal ACE2 expression detected
in many cell lines we examined, whereas in this study, we
focused on cell lines that express greater levels of ACE2 and
are relevant to the clinical sites of infection. Alternatively, the re-
ported differences in ACE2 transcriptional regulation may reflect
cell-type-specific metabolic phenotypes that modulate HIF
signaling (Codo et al., 2020) or expression of co-regulators that
mediate indirect effects of HIF stabilization. For example, a study
of hypoxic regulation of ACE2 in PASMCs suggests an indirect
mechanism through HIF-1a induction of ACE1 and ANG-II/
ATR1 signaling (Zhang et al., 2009); however, ACE1 was not
regulated by hypoxia or FG-4592 in Calu-3 cells (Figure S2).
Interestingly, recent evidence describes a HIF-1a-dependent in-
duction of the microRNA LET7b, which directly targets the ACE2
coding sequence to suppress its expression in hypoxic PASMCs
(Zhang et al., 2019). Although the precise mechanism by which
HIF-1a represses ACE2 mRNA in lung epithelial cells is unclear,
the reversible nature of this repression, combined with the pres-
ence of a hypoxia responsive element in the ACE2 promoter
(Zhang et al., 2009), may be consistent with direct HIF-mediated
repression.
Beyond effects on ACE2-mediated viral entry, we observed
marked suppression of SARS-CoV-2 RNA and genesis of infec-
tious particles by hypoxia or pseudohypoxia. Notably, treatment
with additional prolyl hydroxylase inhibitors Daprodustat and
Molidustat exhibited a comparable antiviral capacity, suggesting
a class effect that extends beyond Roxadustat. HIF has been
shown to regulate the replication of other RNA viruses through
effects on host cell metabolism (Farquhar et al., 2017; Frakolaki
et al., 2018; Zhao et al., 2020a). For example, HIFwas reported to
repress hepatitis C virus replication in the liver via activation ofintra- and extracellular levels of SARS-CoV-2 RNA. The cellular response to
FG-4592 or 1% O2 was assessed through CAIXmRNA quantification. All data
are expressed relative to the UT control. Data are presented as means ± SD
from (A and B) n = 4, and statistical significance was determined using a two-
way ANOVA.
(C) Calu-3 cells were infected with SARS-CoV-2 as detailed above and 8 h later
were cultured under 1%O2 or treated with FG-4592 (50 mM) for 24 h. Intra-
cellular and extracellular viral RNA, along with CAIX transcripts, were
measured by qPCR, and data are expressed relative to UT control.
Data are presented as means ± SD from (A–C) n = 4, and statistical signifi-
cance was determined using a two-way ANOVA. *p < 0.05, **p < 0.01.
A
B C
Figure 4. Hypoxia inhibits SARS-CoV-2 RNA replication
(A) Calu-3 cells were inoculated with SARS-CoV-2 at an MOI of 1.0 for 2 h; unbound virus was removed by washing, and the cells were cultured at 18% or 1%O2
or treated with FG-4592 (50 mM) for 4 h. Cells were fixed, and viral infection was visualized by smFISH, where representative two-dimensional (2D) images
depicting positive-strand SARS-CoV-2 genomic RNA are shown. Cells are counter-stained with DAPI to visualize the nucleus; inset images show the individual
and merged images, and the scale bar depicts 20 mm.
(B) Viral RNAwas quantified by integrating the three-dimensional (3D) signal density of individual cells, in which each symbol represents a single cell at 18%or 1%
O2 or in FG-4592-treated cells.
(C) The frequency of SARS-CoV-2 positive-strand RNA expressing cells at the different oxygen levels and after FG-4592 treatment was quantified per field of
view, in which each symbol reflects a single field.
Data represent the means ± SD percentage of viral RNA derived from n = 3, and significance was assessed by Mann-Whitney test. See also Figure S5.
Report
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OPEN ACCESSthe autotaxin-lysophosphatidic acid signaling pathway to regu-
late virus particle genesis (Farquhar et al., 2017). Moreover, our
understanding of how HIF regulates respiratory viruses is exem-
plified by influenza A virus, whose replication was enhanced in
mice, with HIF-1a inactivation restricted to type II alveolarepithelial cells (Zhao et al., 2020a), highlighting a role for HIF-
1a in repressing this respiratory pathogen. Our findings contrast
to those reported by Codo et al. (2020) who showed that treat-
ment of monocytes with the HIF prolyl hydroxylase inhibitor
BAY 85-3934 (Molidustat) increased SARS-CoV-2 RNA levelsCell Reports 35, 109020, April 20, 2021 7
Report
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OPEN ACCESSin an HIF-1a-dependent manner. This may relate to cell-type-
specific differences; for example, monocytes have limited per-
missivity to support SARS-CoV-2 replication, and viral RNA
levels were substantially lower than those measured from in-
fected lung epithelial cells. Further work is needed to charac-
terize the HIF-1a-dependent mechanisms of SARS-CoV-2
repression described here, which are likely mediated via HIF-
1a regulation of host factors essential for viral RNA replication
and/or stability.
Our observations raise clear questions as to how cellular hyp-
oxia translates to humans, both in terms of SARS-CoV-2 suscep-
tibility and clinical progression of COVID-19. There has been
some speculation that chronic hypoxiamay beprotective,with re-
ports of reduced incidence of COVID-19 disease in high-altitude
human populations (Pun et al., 2020) (although these observa-
tions are complicated by geographic and socioeconomic factors).
Some clinical studies suggest that smokers and patients with
chronic respiratory diseases (e.g., asthma and COPD) are un-
der-represented co-morbidities in hospitalized patients with
COVID-19 (Halpin et al., 2020). However, these conditions are
also associatedwith a higher risk of poor outcomes in established
infections (Lippi and Henry, 2020; Sanchez-Ramirez andMackey,
2020) and,more generally, hypoxemia is a negative prognostic in-
dicator in severe COVID-19 (Berenguer et al., 2020; Petrilli et al.,
2020; Yadaw et al., 2020). Although this is seemingly at odds
with our findings, clinical hypoxemia is a complex state that re-
flects multiple pathogenic processes, including vascular inflam-
mation, coagulopathy, andmicrothrombotic disease (McGonagle
et al., 2020; Varga et al., 2020), which may confound any protec-
tive effects of hypoxia on SARS-CoV-2 infection.
A key finding from our study is the potential therapeutic appli-
cation of Roxadustat, and other related HIF prolyl hydroxylase in-
hibitors, in COVID-19, especially because these act on multiple
stages of the viral life cycle (impairing entry and replication) and,
as such, may be effective against emerging SARS-CoV-2 vari-
ants. These drugs have been developed as erythropoiesis-stimu-
lating agents in patients with anemic and chronic kidney disease
and are currently being used in both pre-dialysis and dialysis set-
tings. Thus, it is likely that substantial numbers of patients who are
at risk of severe COVID-19 (Williamson et al., 2020; Wu et al.,
2020) will be receiving these drugs. Our work highlights the urgent
need to monitor these patients for any evidence that PHD inhibi-
tors provide prophylactic and/or therapeutic activity against
COVID-19. However, clinical translation of Roxadustat may be
complex because HIF has multiple systemic effects that could
affect COVID-19 disease progression. Moreover, ACE2 is protec-
tive in models of lung injury (Kuba et al., 2005), so it is uncertain
whether reducing ACE2 expression would have a net benefit in
severe lung disease. Regardless of the potential complexity, the
marked effects of Roxadustat in protecting naive cells from
SARS-CoV-2 entry and in inhibiting viral replicationwithin infected
cells merits further evaluation in animal models and consideration
for study in human clinical trials.
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Materials availability
This study did not generate new unique reagents.
Data and code availability
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Mendeley Data: https://doi.org/10.17632/yvgx2sgsf6.1.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal procedures were carried out in accordance with the Animals (Scientific Procedures) Act 1986 Amendment Regulations
2012. Mice were housed in the Functional Genetics Facility of the Wellcome Trust Centre for Human Genetics (University of Ox-
ford) in individually ventilated cages with food and water provided ad libitum and on a 13h light/11h dark cycle. Wild-type male
mice on a C57BL/6 genetic background, approximately 8 weeks old and littermate controlled were used for the experiments.
Mice were treated over the course of 24h with 3 oral gavages of 10mg/kg FG-4592 prepared as a 2.5mg/mL solution in 5mg/
mL methyl cellulose, 0.5% Tween80 vehicle (or vehicle alone). Hypoxic mice were housed in a normobaric altitude chamber
held at 10% O2 with controlled temperature, humidity and carbon dioxide levels and compared against mice held in normoxia.
Animals were sacrificed by an overdose of Isoflurane (Primal Critical Care) and exsanguination, after which lungs were collected
and immediately frozen in liquid nitrogen.
Cell culture
RKO, U2-OS, Caco-2 and Vero E6 cell lines were cultured in standard DMEM; SH-SY5Y cell line in DMEM/F-12; Calu-3 in Advanced
DMEM; U937 in RPMI; and A549 in F-12K; all supplemented with: 10% fetal bovine serum, 2mML-glutamine, 100U/mL penicillin and
10 mg/mL streptomycin. EA.hy926 and HepG2 cells were cultured in standard DMEM additionally supplemented with endothelial cell
growth supplement or non-essential amino acids, respectively. All cell lines were maintained at 37C and 5% CO2 in a standard cul-
ture incubator and exposed to hypoxia using an atmosphere-regulated workstation set to 37C, 5%CO2:1%–5%O2:balance N2 (In-
vivo 400, Baker-Ruskinn Technologies). Human PBECs were obtained using flexible fiberoptic bronchoscopy under light sedation
with fentanyl and midazolam from healthy control volunteers. Participants provided written informed consent. The study was re-
viewed by the Oxford Research Ethics Committee B (18/SC/0361). Airway epithelial cells were taken by 2mm diameter cytology
brushes from 3rd to 5th order bronchi and cultured in Airway Epithelial Cell medium (PromoCell, Heidelberg, Germany) in submerged
culture.
Viral strains
SARS-CoV-2 strains: Victoria 01/20 (BVIC01) (Caly et al., 2020) (provided by PHE Porton Down after supply from the Doherty
Centre Melbourne, Australia); B1.1.7 (Tegally et al., 2020) (20I/501Y.V1.HMPP1) (provided by PHE Porton Down) and B1.351
(201/501.V2.HV001) (Cele et al., 2021) (Centre for the AIDS Programme of Research in South Africa) were passaged in Vero E6




SARS-CoV-2 pseudoparticle genesis and infection
SARS-CoV-2 lentiviral pseudoparticles (pp) were generated by transfecting 293T cells with p8.91 (Gag-pol), pCSFW (luciferase re-
porter) and a codon optimized expression construct pcDNA3.1-SARS-CoV-2-Spike, as previously described (Thompson et al.,
2020). The Furin cleavage site mutant was generated by mutagenesis of a pcDNA3.1 based clone expressing a C-terminally flag-
tagged SARS-CoV-2 Spike protein (Wuhan-Hu-1 isolate; MN908947.3). The polybasic cleavage site TNSPRRA in SARS-CoV-2
Spike was replaced with the corresponding SARS-CoV variant sequence SLL. The pNBF SARS-CoV2 FL D614G mutant was a
kind gift from Dr. Daniel Watterson and Dr. Naphak Modhiran (University of Queensland, Australia) and Furin KO mutant from Dr
Daniel Bailey (Pirbright Institute, UK). Supernatants containing viral pp were harvested at 48 and 72h post-transfection. Viral titers
were determined by infecting Calu-3 cells with a serial dilution of virus and 48h later measuring cellular luciferase. As a control for
non-specific lentivirus uptake, stocks were generated with no envelope glycoprotein (No Env). This control was included in all pp
experiments and the luciferase values obtained subtracted from values acquired with the SARS-CoV-2pp. To define spike-depen-
dent infection, SARS-CoV-2pp were incubated with the anti-S-mAb FI-3A (1mg/mL) (Hauang et al., 2020) for 30min prior to infection.
SARS-CoV-2 propagation and infection
Naive Vero E6 cells were infected with SARS-CoV-2 at an MOI of 0.003 and incubated for 48-72h until visible cytopathic effect was
observed. At this point, cultures were harvested, clarified by centrifugation to remove residual cell debris and stored at 80C. Viral
titer was determined by plaque assay. Briefly, Vero E6 cells were inoculated with serial dilutions of SARS-CoV-2 viral stocks for 2h
followed by addition of a semi-solid overlay consisting of 1.5% carboxymethyl cellulose (SIGMA). Cells were incubated for 72h,
visible plaques enumerated by fixing cells using amido black stain and plaque-forming units (PFU) per mL calculated. For infection
of Calu-3 cells with SARS-CoV-2, cells were plated 24h before infection with the stated MOI. Cells were inoculated for 2h after which
the residual inoculum was removed with three PBS washes. Unless otherwise stated, infected cells were maintained for 24h before
harvesting for downstream applications.
Immunoblotting
Cell lysates were prepared bywashing cells with phosphate buffered saline (PBS), then lysing in Igepal lysis buffer (10mMTris pH 7.5,
0.25M NaCl, 0.5% Igepal) supplemented with Complete TM protease inhibitor cocktail (Sigma Aldrich) at 4C for 5min, followed by
clarification by centrifugation (3min, 12,000 rpm). Supernatant was mixed with Laemmli sample buffer, separated by SDS-PAGE and
proteins transferred to polyvinylidene difluoride membrane (Immobilon-P, Millipore). Membranes were blocked in 5% milk in PBS/
0.1% Tween-20, then incubated with anti-ACE2 (Abcam ab108252) or anti-TMPRSS2 (SCBT sc-515727) primary antibodies and
appropriate HRP-conjugated secondary antibodies (DAKO). Chemiluminescence substrate (West Dura, 34076, Thermo Fisher Sci-
entific) was used to visualize proteins using a ChemiDoc XRS+ imaging system (BioRad). Anti-b-actin-HRP conjugate (Abcam
ab49900) and/or Coomassie brilliant blue stainingwas then used to verify equal protein loading and densitometric analysis performed
using ImageJ software (NIH).
RT-qPCR
Cells were washed in PBS then lysed using Tri-reagent (Sigma), and mRNA extracted by phase separation. Equal amounts of cDNA
were then synthesized using the High Capacity cDNA Kit (Applied Biosystems) and mRNA expression determined using Fast SYBR
master mix using a StepOne thermocycler (Applied Biosystems) using the DDCt method. See Key resources table for primer se-
quences. Frozen lungs were homogenized in RLT buffer (QIAGEN) using a Standard Micro-Homogenizer (ProScientific) and
mRNA was extracted using the RNeasy Mini kit (QIAGEN), according to manufacturer’s instructions. Equal amounts of cDNA
were synthesized using the QuantiTect Reverse Transcription Kit (QIAGEN) and mRNA expression was quantified in triplicates in
a duplex quantitative real-time PCR using TaqMan Fast Advanced Master Mix and Ace2 FAM (Mm01159006_m1), Tmprss2 FAM
(Mm00443677_m1), Edn1 FAM (Mm00438656_m1) and ActB VIC (Mm01205647_g1) assays (Thermo Fisher). The reaction was car-
ried out in the StepOnePlus Real-Time PCR System (Applied Biosystems). DCT was defined as the difference between the Target
gene CT and the ActB CT. –DDCT values were calculated for each replicate as follows: -(FG-4592 DCT – Vehicle DCT) (Livak and
Schmittgen, 2001). Fold change in the target gene mRNA expression in each genotype group was expressed as 2–DDCT.
FISH quantification of SARS-CoV-2 RNA
SARS-CoV-2 single-molecule fluorescence in situ hybridization (smFISH): smFISH was carried out as previously reported (Yang
et al., 2017) with minor modifications. Briefly, cells were grown on #0 round glass coverslips in 24 well plate and fixed in 4% para-
formaldehyde for 30min at room temperature. Cells were permeabilised in PBS/0.1% Triton X-100 (PBST) for 10min at room temper-
ature followed by washes in PBS and 2x SSC. Cells were pre-hybridized in prewarmed (37C) wash solution (2x SSC, 10% form-
amide) twice for 20min each at 37C. Hybridization was carried out in hybridization solution (2x SSC, 10% formamide, 10%
dextran sulfate) containing 500nM FISH probes overnight at 37C. SARS-CoV-2 positive and negative genomic RNA FISH probes
were labeled with ATTO633 and ATTO565 (ATTO-Tec), respectively (See Table S1), according to published protocols (Gaspar
et al., 2017). Individual probe sequences are listed in supplemental data. After the overnight hybridization, cells were washed fore4 Cell Reports 35, 109020, April 20, 2021
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OPEN ACCESS20min in pre-warmedwash solution at 37C followed by counterstaining with DAPI (1mg/mL) and Phalloidin-AlexaFluor 488 conjugate
(264nM), diluted in wash solution. Cells were then washed once with wash solution for 20min at 37C and twice with 2xSSC for 5min
each at room temperature. Coverslips were dipped in pure water and mounted on slides using Vectashield HardSet (Vector Labs).
Image acquisition and analysis
Mounted cells were imaged on anOlympus SoRa spinning disc confocal with Orca Flash4CMOS camera using 60x silicone oil objec-
tive (1.3 NA, UPLSAPO60XS2) or 100x silicone oil objective (1.35 NA, UPLSAPO100XS). Specimens were imaged in at least ten
different locations per condition and replicate. 3D-stacked images were taken with voxel size of 80nm x 80nm x 200nm in x:y:z
and images were deconvolved with maximum likelihood algorithm using cellSens (5 iterations, default PSF, Olympus). Background
subtraction was performed on all channels using rolling ball subtraction (radius = 100px) in ImageJ (National Institutes of Health).
smFISH signal was quantified using intensity-based methods by manually segmenting individual infected cells using phalloidin stain
on a maximum projected image and integrating signal intensity across all slices within region of interest. Integrated intensity was
divided by cell volume to obtain signal density per volume, which was normalized by subtracting average signal density of uninfected
cells. Infection frequency was quantified per field of view for each 3D image. To get total number of cells, DAPI channel was Gaussian
filtered (radius = 10px) in ImageJ and nuclei were automatically counted using spot tool in Imaris (diameter = 6mm, Bitplane). Infected
cells were counted manually.
Materials
All reagents and chemicals were obtained from Sigma-Aldrich (now Merck) unless stated otherwise. Roxadustat, Molidustat and
Daprodustat were obtained from either Selleckchem or MedChemExpress. See Key resources table for details
QUANTIFICATION AND STATISTICAL ANALYSIS
Data was analyzed using GraphPad Prism version 8.0.2 (GraphPad, San Diego, CA, (USA). P values < 0.05 were considered signif-
icant; significance values are indicated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Please see individual figure legends for
further details.Cell Reports 35, 109020, April 20, 2021 e5
